Bausch+Lomb Results Presentation Deck
Early Stage Launches and Near-term Pipeline Products to Watch ¹
SiHy Daily
Lumify® Expansion Opportunities
SeeLuma TM Fully Digital Surgical
Visualization Platform (3D Microscope)
eye TELLIGENCE® Digital Platform
IC-8® Apthera ™
MIMSⓇ Minimally Invasive Surgical Procedure
NOV03²
Product
en Vista Envy ™
en Vista® Trifocal IOL
en Vista Aspire ™
en Vista® Extended Range Monofocal IOL
en Vista Beyond ™
en Vista® Extended Depth of Focus IOL
BAUSCH + LOMB
Status
Launched in ~25 countries
Eye Illuminations - Launching this year
Launching now in U.S. and Western Europe
Beta software testing ongoing. Regulatory
assessments complete.
Available in select markets across Europe, as well as
in Australia, New Zealand and Singapore
Entered into exclusive European distribution
agreement with Sanoculis
FDA accepted NDA in September 2022
Canada, EU and U.S submissions in process
US and Canada submitted 1Q23
EU submission planned for 2Q23
Clinical study to begin 3Q23
1. See Slide 1 for further information on forward-looking statements.
2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of
NOV03 in the United States and Canada.
Upcoming Milestone
Planned launch of SVS into more countries in
2023; Multi-focal and toric launch expected in
2023-2024
Preservative Free submission expected 2Q23
Allergy submission expected 1Q24
Additional countries expected to follow
U.S. commercial release in process
U.S launch in process
EU launch in process
PDUFA date June 28, 2023
Filed in Canada 1Q23
Expect US, EU, Canada launch in 2024
(includes Toric versions and new EyeGility inserter)
Expect US and Canada launch 2H23
(includes Toric; new EyeGility inserter to be added in 2024)
EU launch expected in 2024 with EyeGility inserter
Expect 2025/2026 launch
20View entire presentation